ÁZÁdám Zolcsák

Ádám Zolcsák

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ádám Zolcsák has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis

    by Orsolya Eperjesi, Maria Bucur, Anett Rancz, Ádám Zolcsák, Marie Anne Engh, Mahmoud Obeidat, Andrea Szentesi, Péter Hegyi, Stefania Bunduc


  • Open Access

    Titin’s Intrinsically Disordered PEVK Domain Modulates Actin Polymerization

    by Áron Gellért Altorjay, Hedvig Tordai, Ádám Zolcsák, Nikoletta Kósa, Tamás Hegedűs, Miklós Kellermayer

    The multi-domain muscle protein titin provides elasticity and mechanosensing functions to the sarcomere. Titin’s PEVK domain is intrinsically disordered due to the presence of a large number of prolines and highly charged residues. Although PEVK does not have canonical actin-binding motifs, it has been shown to bind F-actin. Here, we explored whether the PEVK domain may also affect actin assembly. We cloned the middle, 733-residue-long segment (called PEVKII) of the full-length PEVK domain, expressed in E. coli and purified by using His- and Avi-tags engineered to the N- and C-termini, respectively. Actin assembly was monitored by the pyrene assay in the presence of varying PEVKII concentrations. The structural features of PEVKII-associated F-actin were studied with atomic force microscopy. The added PEVKII enhanced the initial and log-phase rates of actin assembly and the peak F-actin quantity in a concentration-dependent way. However, the critical concentration of actin polymerization was unaltered. Thus, PEVK accelerates actin polymerization by facilitating its nucleation. This effect was highlighted in the AFM images of F-actin–PEVKII adsorbed to the supported lipid bilayer. The sample was dominated by radially symmetric complexes of short actin filaments. PEVK’s actin polymerization-modulating effect may, in principle, have a function in regulating sarcomeric actin length and turnover. Altogether, titin’s PEVK domain is not only a non-canonical actin-binding protein that regulates sarcomeric shortening, but one that may modulate actin polymerization as well.


  • Open Access

    End-to-end anastomosis provides similar quality-of-life, compared with other reconstructive techniques six months following total mesorectal excision: Systematic review and meta-analysis

    by Sarolta Beáta Kávási, Diana - Elena Iov, Anett Rancz, Ádám Zolcsák, Dániel Sándor Veres, Katalin Lenti, Pál Miheller, Péter Hegyi, Szabolcs Ábrahám


  • Open Access

    The risk of developing splanchnic vein thrombosis in acute pancreatitis increases 3 days after symptom onset: A systematic review and meta‐analysis

    by Ruben Zsolt Borbély, Eszter Ágnes Szalai, Bryan Mangalath Philip, Dalma Dobszai, Brigitta Teutsch, Ádám Zolcsák, Dániel Sándor Veres, Bálint Erőss, Bálint Gellért, Péter Jenő Hegyi, et al.

    Background: Splanchnic vein thrombosis is a complication of acute pancreatitis (AP) and is likely often underdiagnosed.Objectives: We aimed to understand the time course and risk factors of splanchnic vein thrombosis in the early phase of AP.Methods: A systematic search was conducted using the PRISMA guidelines (PROSPERO registration CRD42022367578). Inclusion criteria were appropriate imaging techniques in adult AP patients, studies that reported splanchnic vein thrombosis data from the early phase, and reliable information on the timing of imaging in relation to the onset of pancreatitis symptoms or hospital admission. The proportion of patients with thrombosis with 95% confidence intervals (CI) was calculated using random‐effects meta‐analyses, and multiple subgroup analyses were performed.Results: Data from 1951 patients from 14 studies were analyzed. The proportion of patients with splanchnic vein thrombosis within 12 days after symptom onset was 0.13 (CI 0.07–0.23). The occurrence was lowest at 0.06 (CI 0.03–0.1) between 0 and 3 days after symptom onset, and increased fourfold to 0.23 (CI 0.16–0.31) between 3 and 11 days. On hospital admission, the proportion of patients affected was 0.12 (CI 0.02–0.49); it was 0.17 (CI 0.03–0.58) 1–5 days after admission. The prevalence in mild, moderate, and severe AP was 0.15 (CI 0.05–0.36), 0.26 (CI 0.15–0.43), and 0.27 (CI 0.17–0.4), respectively. Alcoholic etiology (0.31, CI 0.13–0.58) and pancreatic necrosis (0.55, CI 0.29–0.78, necrosis above 30%) correlated with increased SVT prevalence.Conclusion: The risk of developing splanchnic vein thrombosis is significant in the early stages of AP and may affect up to a quarter of patients. Alcoholic etiology, pancreatic necrosis, and severity may increase the prevalence of splanchnic vein thrombosis.


  • Open Access

    Supplementary Respiratory Therapy Improves Pulmonary Function in Pediatric Patients with Cerebral Palsy: A Systematic Review and Meta-Analysis

    by Erika Kolumbán, Márton Szabados, Márk Hernádfői, Uyen Nguyen Do To, Rita Nagy, Ádám Zolcsák, Katalin Eszter Müller, Zoltán Sipos, Dániel Sándor Veres, Anett Szőllősi, et al.

    Background: Despite medical advances, individuals with cerebral palsy (CP) face significant respiratory challenges, leading to heightened hospitalization rates and early mortality among this population. We hypothesize that integrating supplementary respiratory therapy into standard rehabilitation will result in significant improvements in pulmonary function, enhanced respiratory muscle strength, and an overall increase in the quality of life among pediatric patients with CP. Methods: A systematic search of literature across five databases was conducted, and random-effects meta-analyses were performed to assess the impact of supplementary respiratory therapy on (a) pulmonary function: forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FVC/FEV1 ratio, peak expiratory flow (PEF), and (b) respiratory muscle strength: maximal inspiratory and expiratory pressure (MIP, MEP), and (c) quality of life. Certainty of evidence was determined by the GRADE assessment. Results: Analysis of data from 11 eligible randomized controlled trials revealed clinically meaningful changes in pulmonary function. We found a relevant mean difference (MD) in absolute PEF of 0.50 L/s (95% confidence interval (CI): 0.19; 0.82 p = 0.0107). The certainty of the evidence ranged from moderate to high. Conclusions: This study presents current evidence on the impact of various supplementary respiratory therapies for CP patients classified under gross motor function classification level I–IV, demonstrating clinically meaningful improvements in pulmonary function and respiratory muscle strength. These improvements suggest the potential for an enhanced quality of life. Our findings hold the promise of serving as a foundational reference for potential revisions to conventional rehabilitation care, incorporating supplementary respiratory therapy.